Pessary Market Size, Share & Trends Analysis Report By Type (Gellhorn, Ring, Donut), By End-use (Hospitals, Ambulatory Surgical Centers, Clinics), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global pessary market size was exhibited at USD 412.80 million in 2023 and is projected to hit around USD 659.71 million by 2033, growing at a CAGR of 4.8% during the forecast period of 2024 to 2033.

Key Takeaways:

• The ring segment dominated the pessary market with a revenue share of 56.9% in 2023.
• The hospital segment accounted for the largest market revenue share of 45.0% in 2023.
• North America dominated the market and accounted for the largest revenue share of 43.0% in 2023.

Pessary Market Report Scope

The increasing prevalence of pelvic organ prolapse, the growing geriatric population that is prone to this condition, easy product availability, changing lifestyles, and rapid evolution of noninvasive treatment options are expected to fuel market growth. Stress urine incontinence is higher in patients with poor nutritional status, which results in the weakening of pelvic muscles. Thus, the demand for advanced pelvic support devices is expected to show steep growth in the coming years.

Vaginal pessaries are one of the most preferred treatment options for organ prolapse and incontinence, as they are considered simple, affordable, and safe solutions. These factors contribute to a higher patient satisfaction rate as compared to their alternatives. Thus, vaginal pessaries are considered a first-line treatment for pelvic prolapse and/or stress urinary incontinence. Pelvic organ prolapse (POP) affects women of all ages; however, elderly women are more susceptible to POP. As per a 2019 report by the US FDA, the number of women with POP is poised to rise by 46% to 4.9 million by 2050.

Pessaries were preferred as a temporary measure against delayed elective surgeries during COVID-19. However, the overall demand declined greatly during the first pandemic wave, owing to a decrease in the overall footfall in clinics and hospitals during this period. Lockdowns and movement restrictions directly affected production; however, these units started reopening during the third quarter of 2020. The adoption of vaginal pessaries is impacted by factors such as patient discomfort and fear of side effects. To address these issues, regulatory agencies such as the FDA and NICE have developed new guidelines for manufacturers.

Pessaries are in greater demand due to the increased prevalence of pelvic organ prolapse and urine incontinence. As per a November 2021 International Urogynecology Journal article, approximately 40% of women suffer from pelvic organ prolapse (POP). Pessary treatment has demonstrated a high degree of patient satisfaction (75.3%), efficacy (90.7%), and a positive impact on the improvement of vaginal and sexual symptoms, quality of life, and mental health. The same source states that the most commonly used kind of ring pessary that permits sexual activity while retaining less vaginal discharge is the membrane-free variety, which is superior to occlusive (Gellhorn) types or devices.

Frequent product launches, geographical expansions, heavy focus on R&D by market players and universities, and government initiatives are the major factors likely to boost market growth. Cosm Medical Corporation received Health Canada Investigational Testing Authorization (ITA) approval in February 2021 for a clinical study for its Gynethotics customized gynecological prosthetics. Cosm designs the pessary according to a patient's specific anatomy and lifestyle needs with a modernized pelvic floor measurement system, using novel ultrasound imaging technology.

Type Insights

The ring segment dominated the pessary market with a revenue share of 56.9% in 2023. The segment is expected to expand at a significant CAGR throughout the forecast period, owing to factors such as ease of usage and patient comfort. The ring pessary is appropriate for all stages of POP. Clinicians favor ring pessaries because of the simplicity with which they can be inserted and removed. These are most effective in the early stages of prolapse, but they can be used at any stage of pelvic organ prolapse.

Gehrung, shaatz, oval, cube, and shelf are few other pessaries that are widely used. Other support pessaries can be more useful for advanced prolapse but are more difficult for the patient to handle. The device uses suction to support areas that may be sagging or bulging due to prolapse. Most of the pessaries available in the market currently are comprised of silicone, a highly compatible material. It is non-allergenic, long-lasting, autoclavable, and simple to remove & replace. The type of pessary to be used is determined by a number of parameters, including the type and degree of prolapse.

End-use Insights

The hospital segment accounted for the largest market revenue share of 45.0% in 2023. This demand is owing to the extensive use of pessaries in post-operative and bedridden in-patients. Increasing awareness about organ prolapse, urinary incontinence, and inclusion of pessaries in private insurances are some of the factors boosting segment growth. Also, hospitals are adopting minimally invasive procedures for pessary placement to reduce post-operative complications and accelerate the recovery rate.

The clinic segment is expected to witness the fastest CAGR of 5.2% during the forecast period. This can be attributed to affordable pessary fitting procedures, limited stay duration, and higher convenience for the geriatric population in this setting. Ambulatory surgical centers are also expected to grow at a significant rate during the forecast period, on account of the rising awareness about ambulatory centers among the general population.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 43.0% in 2023. The market has a high impact on the region due to factors such as an aging female population, lifestyle changes that cause hormonal disruptions, the rising prevalence of pelvic organ prolapse, and increased health awareness. According to an article in the National Library of Medicine, 3.3 million women in the U.S. experienced pelvic organ prolapse in 2010, and this number is expected to rise to 4.9 million by 2050 due to a probable link with aging.

In Asia Pacific, the market for pessaries is expected to witness exponential growth over the forecast period. The regional market's CAGR of 5.4% is expected to be linked to emerging economies, a rapidly aging population, and increased healthcare awareness. The geriatric population is more vulnerable to urinary incontinency and POP, providing a large target market in the region, with Japan, China, and India being the primary regional providers. Additionally, increasing medical tourism is another important element driving regional market expansion.

Recent Developments

In December 2023, Integra LifeSciences Holdings Corporation announced that it had successfully acquired Surgical Innovation Associates (SIA)

In November 2023, CooperSurgical, Inc. announced the signing of a definitive purchase agreement to acquire Generate Life Sciences, a notable name in the space of cryopreservation of donor eggs and sperm for use in fertility treatments, as well as the storage of newborn stem cells (cord blood & tissue)

Some of the prominent players in the pessary market include:

• CooperSurgical Inc.
• Bliss GVS Pharma
• MedGyn
• Panpac Medical Corporation
• Bioteque America
• Personal Medical Corporation
• Dr. Arabin GmbH & Co. KG
• Integra LifeSciences
• Wallach Surgical Devices

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global pessary market.

Type

• Gellhorn
• Ring
• Donut
• Others

End-use

• Hospitals
• Ambulatory Surgical Centers
• Clinics

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)